[Evaluation of the efficacy of praziquantel-liposome against alveococcosis].
In this paper, praziquantel, an anti-hydatidosis drug, was encapsulated with liposome by REV (Reverse-phase-evaporation) method, the encapsulated percentage was 60%. The drug distribution dynamics in mice of both praziquantel (PZQ) and praziquantel liposome (PZQ-Lip) were determined using RP-HPLC method. The results indicated that the drug concentration of blood, liver and spleen in the PZQ-Lip group was higher than those in the PZQ group from 1/2 to 16 hours post ip. the t1/2 of the former was considerably prolonged. The toxicity of PZQ-Lip tested by LD50 was decreased about one fourth as compared with PZQ (3372 vs. 2,454 mg/kg). There was a significant difference in the cyst inhibition rate between PZQ-Lip group (68.7%) and PZQ group (14.3%) (P < 0.01) as shown by the results of secondary alveocococcosis mice treated with either drug at 500 mg/kg.d x 12 d for four consecutive courses. Histological observation of the germinal layer after treatment showed that the damage of PZQ-Lip group was more severe than that of PZQ group. The ultrastructural observation showed that both drugs had marked effects on the organelles of cells. The above experiments indicated that the efficacy of PZQ-Lip was more effective than PZQ for treatment of alveococcosis.
Li
F R
FR
Hydatid Research Laboratory, Lanzhou Medical College.
Jiang
C P
CP
Cao
H X
HX
Wang
Q
Q
D000818:Animals; D004337:Drug Carriers; D004444:Echinococcosis, Hepatic / Q000188:drug therapy* / Q000378:metabolism; D005260:Female; D007928:Lethal Dose 50; D008081:Liposomes; D008297:Male; D051379:Mice; D011223:Praziquantel / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000633:toxicity
D004337:Drug Carriers; D008081:Liposomes; D011223:Praziquantel